Teva's MS Drug Nails Primary Endpoints – and Then Some

Teva Pharmaceutical Industries Ltd. has reported that its oral laquinimod for relapsing-remitting multiple sclerosis (RRMS) hit the primary endpoint in its two-year Phase III ALLEGRO study, demonstrating significant reduction in annualized relapse rate compared to placebo.